Health & Fitness
Health and Fitness
Health and Fitness
Fri, October 14, 2011
Thu, October 13, 2011
Cannabis Science Packaging its First Cannabis-Extract-Based Formulation Slated For October 2011 Colorado State Distribution As
DENVER--([ BUSINESS WIRE ])--Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the initial product analyzing and production run has been completed and the commercial packaging process is now underway. This will be the first set of Cannabis Science brand formulations being released, scheduled for later this month through its producing lab and initial Colorado State licensed dispensary. The Companya™s CEO, Dr. Robert Melamede, has chosen specially selected medical marijuana dispensaries in Colorado that will offer the Cannabis Science formulations to patients in accordance with Colorado State laws and regulations.
Dr. Robert Melamede, Ph.D., the Companya™s CEO, said, aWe hear from so many people wanting a reliable, high-quality formulation that they can self-administer to treat a wide variety ailments. A quality, standardized formulation is essential for long term care. As far as I know, we have the only formulation made from organically grown cannabis bud, and produced in a professional, Colorado State licensed, laboratory facility. Initially, we have chosen two facilities in Colorado to work with, both of the facilities were chosen for the quality of their botanicals and patient care. We are looking forward to expanding availability to other legal medical marijuanafacilities and States along with an increased multiple formulation offerings.a
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
